Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study

M. Rinzivillo, N. Fazio, S. Pusceddu, A. Spallanzani, T. Ibrahim, D. Campana, R. Marconicini, S. Partelli, G. Badalamenti, M.P. Brizzi, L. Catena, G. Schinzari, C. Carnaghi, R. Berardi, A. Faggiano, L. Antonuzzo, F. Spada, S. Gritti, D. Femia, F. GelsominoA. Bongiovanni, S. Ricci, N. Brighi, M. Falconi, G. Delle Fave, F. Panzuto

Research output: Contribution to journalArticlepeer-review


Introduction: Besides data reported in a Phase-III trial, data on sunitinib in pancreatic Neuroendocrine Tumors (panNETs) are scanty. Aim: To evaluate sunitinib efficacy and tolerability in panNETs patients treated in a real-world setting. Patients and methods: Retrospective analysis of progressive panNETs treated with sunitinib. Efficacy was assessed by evaluating progression-free survival, overall survival, and disease control (DC) rate (stable disease (SD) + partial response + complete response). Data are reported as median (25th–75th IQR). Results: Eighty patients were included. Overall, 71.1% had NET G2, 26.3% had NET G1, and 2.6% had NET G3 neoplasms. A total of 53 patients (66.3%) had received three or more therapeutic regimens before sunitinib, with 24 patients (30%) having been treated with four previous treatments. Median PFS was 10 months. Similar risk of progression was observed between NET G1 and NET G2 tumors (median PFS 11 months and 8 months, respectively), and between patients who had received ≥ 3 vs ≤ 2 therapeutic approaches before sunitinib (median PFS 9 months and 10 months, respectively). DC rate was 71.3% and SD was the most frequent observed response, occurring in 43 pts (53.8%). Overall, 59 pts (73.8%) experienced AEs, which were grade 1–2 in 43 of them (72.9%), grade 3 in 15 pts (25.4%), and grade 4 in one patient (1.7%). Six pts (7.5%) stopped treatment due to toxicity. Conclusions: The present real-world experience shows that sunitinib is a safe and effective treatment for panNETs, even in the clinical setting of heavily pre-treated, progressive diseases. © 2018 IAP and EPC
Original languageEnglish
Pages (from-to)198-203
Number of pages6
Issue number2
Publication statusPublished - 2018


  • Neuroendocrine tumors
  • Pancreas
  • Progressive disease
  • Sunitinib
  • Target therapy
  • antineoplastic agent
  • everolimus
  • somatostatin derivative
  • sunitinib
  • indole derivative
  • pyrrole derivative
  • adult
  • aged
  • Article
  • asthenia
  • cancer staging
  • cancer survival
  • diarrhea
  • disease control
  • drug efficacy
  • drug safety
  • drug withdrawal
  • female
  • fever
  • hand foot syndrome
  • human
  • hypertension
  • major clinical study
  • male
  • mucosa inflammation
  • neutropenia
  • overall survival
  • pancreas islet cell tumor
  • priority journal
  • progression free survival
  • radioisotope therapy
  • retrospective study
  • stomatitis
  • thrombocytopenia
  • Italy
  • middle aged
  • neuroendocrine tumor
  • pancreas tumor
  • treatment outcome
  • Adult
  • Aged
  • Antineoplastic Agents
  • Humans
  • Indoles
  • Middle Aged
  • Neuroendocrine Tumors
  • Pancreatic Neoplasms
  • Pyrroles
  • Retrospective Studies
  • Treatment Outcome


Dive into the research topics of 'Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study'. Together they form a unique fingerprint.

Cite this